Tovorafenib
Orphan DrugFDA Approved (2024)
Description
An oral type II RAF inhibitor for relapsed or refractory pediatric low-grade glioma with BRAF fusions or the V600 mutation. FDA-approved April 2024.
Indications & Therapeutic Use
Pediatric low-grade glioma
Global Availability (1 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| Standard Marketing Authorization | — | — | Approved |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Tovorafenib
| Generic Name | tovorafenib |
| Brands | 1 brand available |
| Active Ingredient | tovorafenib |
| Drug Class | Pediatric low-grade glioma |
| Manufacturer | Day One Biopharmaceuticals |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Reg. Status | FDA Approved (2024) |
| Countries | 1 countries |
Authority Signals
Last Verified7/24/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations2 Validated Nodes